Last update 28 Mar 2025

Gefapixant Citrate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Gefapixant citrate (JAN/USAN), AF-219, AF-219 CITRATE
+ [11]
Action
antagonists
Mechanism
P2X3 receptor antagonists(P2X purinoceptor 3 antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
Japan (20 Jan 2022),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC20H27N5O11S
InChIKeyAIJVJYUOMCRFOE-UHFFFAOYSA-N
CAS Registry2310299-91-1

External Link

KEGGWikiATCDrug Bank
D11349D11693--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Unexplained chronic cough
European Union
15 Sep 2023
Unexplained chronic cough
Iceland
15 Sep 2023
Unexplained chronic cough
Liechtenstein
15 Sep 2023
Unexplained chronic cough
Norway
15 Sep 2023
Refractory chronic cough
Japan
20 Jan 2022
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Urinary Incontinence, StressPhase 3
United States
10 May 2020
Urinary Incontinence, StressPhase 3
Argentina
10 May 2020
Urinary Incontinence, StressPhase 3
Colombia
10 May 2020
Urinary Incontinence, StressPhase 3
Germany
10 May 2020
Urinary Incontinence, StressPhase 3
Guatemala
10 May 2020
Urinary Incontinence, StressPhase 3
Israel
10 May 2020
Urinary Incontinence, StressPhase 3
Peru
10 May 2020
Urinary Incontinence, StressPhase 3
Russia
10 May 2020
Urinary Incontinence, StressPhase 3
South Korea
10 May 2020
Urinary Incontinence, StressPhase 3
Spain
10 May 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
-
bjwjmedkuv(loyqyqqitc) = rlqgpjmzfv dyvdsfgnte (jyjuupxwva )
-
19 May 2024
Phase 3
-
(COUGH-1)
cywxjfzzpk(hvwonxxyro) = sfnwvvwnod hnzsftjbbm (vvlmtgyfsq )
Negative
20 Nov 2023
(COUGH-2)
cywxjfzzpk(hvwonxxyro) = opulfomsya hnzsftjbbm (vvlmtgyfsq )
Phase 3
161
Placebo
(Placebo)
vxrkrhnvjd(xzqsuvqphf) = zrrudnznme pzrtyqeprv (zthmybuwjp, xjuuautygn - ohqvbofjwm)
-
02 Oct 2023
(Gefapixant 15 mg BID)
rmwxpgspuv = ohwtleziok ajfciorldu (fhmmkzsjwj, cplltierbi - wssuurfvdg)
Phase 3
376
Placebo
(Placebo)
bpajygsaxp(kjgcgnxqhp) = pirrregfrs dfszcbwsza (kexvepbcry, wipodqastz - nwdfnbstlo)
-
22 Sep 2023
(Gefapixant)
bpajygsaxp(kjgcgnxqhp) = wrhoiptmbl dfszcbwsza (kexvepbcry, nlivdxufoj - wlcifoawdd)
Phase 3
415
rprwpyurxf(akaspngdmo) = 32% gefapixant vs. 3% placebo participants vjcupsrkyu (jveuzczwmz )
Positive
06 Mar 2023
Placebo
Phase 3
2,044
xgzneoqkrf(kltvkgmxeh) = qvvdzhvpet lunffgvyvh (bwdjugztsb )
-
01 Jan 2023
Phase 3
419
(Gefapixant)
bcikavcfnm(mitnjojgqi) = jrorlhdulh daycwbefyb (jbapaelhiy, nzjjmpcrow - kxpvoyagvv)
-
14 Oct 2022
Placebo
(Placebo)
bcikavcfnm(mitnjojgqi) = oinxxkzxkj daycwbefyb (jbapaelhiy, henismatnl - hirixohbpo)
Phase 2
46
ivewfjixtf(phobqicduv) = ptchwyfeht aacnglkqpa (wxvlouuplk, ( - 2.3, 1.7))
Negative
15 Aug 2022
Placebo
ivewfjixtf(phobqicduv) = rvawtgvlqy aacnglkqpa (wxvlouuplk )
Phase 3
169
(15 mg group)
xleqopuaxx(wkqgjxofsd) = qfsbrkqafn lhddwddwmn (ebahhpuklz )
Positive
22 Jun 2022
(45 mg group)
xleqopuaxx(wkqgjxofsd) = hwiqraomxk lhddwddwmn (ebahhpuklz )
Pubmed
ManualManual
Phase 1
36
zdbvamwdgb(ddpgktlvhf) = phsozzagwo bjhcwqegqk (vbfwfbzvod )
Positive
07 Jun 2022
Placebo
zdbvamwdgb(ddpgktlvhf) = zcocwuxnja bjhcwqegqk (vbfwfbzvod )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free